Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mdgl · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Madrigal Pharmaceuticals, Inc. (MDGL) measures how much investors pay for each dollar of the company's trailing earnings. MDGL's current PE ratio of N/A is calculated by dividing its stock price of $486.98 by its TTM earnings per share of -$10.66.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Madrigal Pharmaceuticals, Inc.You MDGL | $11.2B | N/A | — | -$10.66 |
 Abivax S.A. ABVX | $6.7B | N/A | — | -$4.83 |
 Baxter International Inc. BAX | $10.0B | N/A | — | -$1.87 |
 BioMarin Pharmaceutical Inc. BMRN | $11.0B | 32.67x | +36.7% | $1.82 |
 Caris Life Sciences, Inc. CAI | $4.7B | N/A | — | -$0.32 |
 Exelixis, Inc. EXEL | $13.2B | 15.12x | -36.7% | $2.88 |
 Jazz Pharmaceuticals plc JAZZ | $15.0B | N/A | — | -$5.84 |
Industry Average 2 peers with valid PE | — | 23.90x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-12.85 | — | |
2024-12-31 FY2024 | — | $-21.90 | — | |
2023-12-31 FY2023 | — | $-19.99 | — | |
2022-12-31 FY2022 | — | $-17.23 | — | |
2021-12-31 FY2021 | — | $-14.63 | — | |
2020-12-31 FY2020 | — | $-13.09 | — | |
2019-12-31 FY2019 | — | $-5.45 | — | |
2018-12-31 FY2018 | — | $-2.22 | — | |
2017-12-31 FY2017 | — | $-2.54 | — | |
2016-12-31 FY2016 | — | $-5.07 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Madrigal Pharmaceuticals, Inc. (MDGL) measures how much investors pay for each dollar of the company's trailing earnings. MDGL's current PE ratio of N/A is calculated by dividing its stock price of $486.98 by its TTM earnings per share of -$10.66.
Frequently asked questions
MDGL pe ratio · 6 questionsMDGL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $486.98 and TTM EPS of -$10.66. Data sourced from Financial Modeling Prep via MDGL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Madrigal Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08